Veryan Medical
Veryan Medical Limited is a company specializing in innovative vascular intervention devices, notably the BioMimics 3D Vascular Stent System. The company is part of the Otsuka Medical Devices group and has a strong focus on biomimicry technology to improve clinical outcomes in vascular treatments. With a history dating back to 2005, originating from Imperial College London, Veryan applies design intelligence and research to develop medical devices that enhance patient care. The company has regulatory approvals including FDA, CE Mark, and Japanese Shonin, and is committed to delivering long-term benefits through its advanced stent designs and clinical research programs.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Three‑dimensional helical self‑expanding nitinol peripheral vascular stent
A self‑expanding peripheral stent using three‑dimensional helical geometry intended for femoropopliteal implantation; designed to modify local flow and vessel mechanics to reduce strain and fracture risk.
Three‑dimensional helical self‑expanding nitinol peripheral vascular stent
A self‑expanding peripheral stent using three‑dimensional helical geometry intended for femoropopliteal implantation; designed to modify local flow and vessel mechanics to reduce strain and fracture risk.
Services
Design, sponsor and manage prospective clinical studies and registries with imaging core‑lab support and independent clinical event adjudication.
Advisory and submission support for regional approval strategies including investigational device pathways and premarket approval/clearance routes.
Execution of market launch activities, deployment of direct sales teams and establishment of distributor networks for vascular devices.
Design, sponsor and manage prospective clinical studies and registries with imaging core‑lab support and independent clinical event adjudication.
Advisory and submission support for regional approval strategies including investigational device pathways and premarket approval/clearance routes.
Execution of market launch activities, deployment of direct sales teams and establishment of distributor networks for vascular devices.
Expertise Areas
- Peripheral vascular device design
- Hemodynamic and biomechanical engineering for implants
- Clinical trial management for medical devices (RCTs, IDE studies, registries)
- Regulatory strategy and approvals (FDA, CE marking)
Key Technologies
- Self‑expanding nitinol stent construction
- Three‑dimensional helical implant geometry
- Hemodynamic flow engineering (swirling flow design)
- Clinical trial methodologies (randomized trials, multicentre registries, IDE studies)
News & Updates
Professor Thomas Zeller presented the 36-month clinical outcomes showing 81% freedom from CDTLR at 3 years, supporting the long-term efficacy of the BioMimics 3D stent.
The system received regulatory approval in Japan for treating symptomatic peripheral arterial disease, including occlusion cases.
Veryan announced the launch of the BioMimics 3D Vascular Stent System in the US, highlighting its unique design and clinical benefits.
Nick Yeo, after 11 years of service, left Veryan to pursue new goals. Chas Taylor was appointed Interim CEO.
An overview of Veryan's strategic approach to innovation and market growth.
Highlights of recent media coverage and company achievements.
Professor Thomas Zeller presented the 36-month clinical outcomes showing 81% freedom from CDTLR at 3 years, supporting the long-term efficacy of the BioMimics 3D stent.
The system received regulatory approval in Japan for treating symptomatic peripheral arterial disease, including occlusion cases.
Veryan announced the launch of the BioMimics 3D Vascular Stent System in the US, highlighting its unique design and clinical benefits.
Nick Yeo, after 11 years of service, left Veryan to pursue new goals. Chas Taylor was appointed Interim CEO.
An overview of Veryan's strategic approach to innovation and market growth.
Highlights of recent media coverage and company achievements.